C-J Chiu1, R Klein, R C Milton, G Gensler, A Taylor. 1. Laboratory for Nutrition and Vision Research, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA. cj.chiu@tufts.edu
Abstract
BACKGROUND: Recent information suggests that the Age-Related Eye Disease Study (AREDS) supplement, enhanced intake of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and reducing dietary glycaemic index (dGI) are protective against advanced age-related macular degeneration (AMD). METHODS: Dietary information was collected at baseline, and fundus photograph grades were obtained during the 8-year trial period from 2924 eligible AREDS AMD trial participants. Using the eye as the unit of analysis and multifailure Cox proportional-hazards regression, the risk of AMD progression was related to dietary intake in the four arms of the trial. RESULTS: Independent of AREDS supplementation, higher intakes of DHA (> or =64.0 vs <26.0 mg/day) (hazard ratio (HR) = 0.73, 95% confidence interval (CI), 0.57 to 0.94), EPA (> or =42.3 vs <12.7 mg/day) (HR = 0.74, 95% CI 0.59 to 0.94), and lower dGI (dGI, <75.2 vs > or =81.5) (HR = 0.76, 95% CI 0.60 to 0.96) were associated with a lower risk for progression to advanced AMD. Participants consuming a lower dGI and higher DHA or EPA had the lowest risk (p value for synergistic interaction <0.001). Only participants in the "placebo" (p value for antagonistic interaction = 0.006) benefited from a higher DHA intake against early AMD progression (HR = 0.58, 95% CI 0.37 to 0.92; P(trend) = 0.01). CONCLUSIONS: The findings show an association of consuming a diet rich in DHA with a lower progression of early AMD. In addition to the AREDS supplement, a lower dGI with higher intakes of DHA and EPA was associated with a reduced progression to advanced AMD. TRIAL REGISTRATION NUMBER: NCT00000145.
RCT Entities:
BACKGROUND: Recent information suggests that the Age-Related Eye Disease Study (AREDS) supplement, enhanced intake of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and reducing dietary glycaemic index (dGI) are protective against advanced age-related macular degeneration (AMD). METHODS: Dietary information was collected at baseline, and fundus photograph grades were obtained during the 8-year trial period from 2924 eligible AREDSAMD trial participants. Using the eye as the unit of analysis and multifailure Cox proportional-hazards regression, the risk of AMD progression was related to dietary intake in the four arms of the trial. RESULTS: Independent of AREDS supplementation, higher intakes of DHA (> or =64.0 vs <26.0 mg/day) (hazard ratio (HR) = 0.73, 95% confidence interval (CI), 0.57 to 0.94), EPA (> or =42.3 vs <12.7 mg/day) (HR = 0.74, 95% CI 0.59 to 0.94), and lower dGI (dGI, <75.2 vs > or =81.5) (HR = 0.76, 95% CI 0.60 to 0.96) were associated with a lower risk for progression to advanced AMD. Participants consuming a lower dGI and higher DHA or EPA had the lowest risk (p value for synergistic interaction <0.001). Only participants in the "placebo" (p value for antagonistic interaction = 0.006) benefited from a higher DHA intake against early AMD progression (HR = 0.58, 95% CI 0.37 to 0.92; P(trend) = 0.01). CONCLUSIONS: The findings show an association of consuming a diet rich in DHA with a lower progression of early AMD. In addition to the AREDS supplement, a lower dGI with higher intakes of DHA and EPA was associated with a reduced progression to advanced AMD. TRIAL REGISTRATION NUMBER: NCT00000145.
Authors: Serge Resnikoff; Donatella Pascolini; Daniel Etya'ale; Ivo Kocur; Ramachandra Pararajasegaram; Gopal P Pokharel; Silvio P Mariotti Journal: Bull World Health Organ Date: 2004-12-14 Impact factor: 9.408
Authors: T M Wolever; P M Nguyen; J L Chiasson; J A Hunt; R G Josse; C Palmason; N W Rodger; S A Ross; E A Ryan; M H Tan Journal: Am J Clin Nutr Date: 1994-06 Impact factor: 7.045
Authors: D J Jenkins; T M Wolever; R H Taylor; H Barker; H Fielden; J M Baldwin; A C Bowling; H C Newman; A L Jenkins; D V Goff Journal: Am J Clin Nutr Date: 1981-03 Impact factor: 7.045
Authors: David J A Jenkins; Cyril W C Kendall; Livia S A Augustin; Silvia Franceschi; Maryam Hamidi; Augustine Marchie; Alexandra L Jenkins; Mette Axelsen Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: John Paul SanGiovanni; Emily Y Chew; Elvira Agrón; Traci E Clemons; Frederick L Ferris; Gary Gensler; Anne S Lindblad; Roy C Milton; Johanna M Seddon; Ronald Klein; Robert D Sperduto Journal: Arch Ophthalmol Date: 2008-09
Authors: Chung-Jung Chiu; Paul Mitchell; Ronald Klein; Barbara E Klein; Min-Lee Chang; Gary Gensler; Allen Taylor Journal: Ophthalmology Date: 2014-03-18 Impact factor: 12.079
Authors: Paul S Bernstein; Faisal Ahmed; Aihua Liu; Susan Allman; Xiaoming Sheng; Mohsen Sharifzadeh; Igor Ermakov; Werner Gellermann Journal: Invest Ophthalmol Vis Sci Date: 2012-09-14 Impact factor: 4.799
Authors: Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2011-11-25 Impact factor: 4.799
Authors: Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2012-02-02 Impact factor: 4.799
Authors: Hema L Ramkumar; Jingsheng Tuo; De F Shen; Jun Zhang; Xiaoguang Cao; Emily Y Chew; Chi-Chao Chan Journal: J Nutr Date: 2013-05-15 Impact factor: 4.798